Structure Based Design of Anti-Parkinson's Disease Compounds Targeting Synuclein Oligomerization
Recent work by UC San Diego investigators have focused on a specific region of alpha-synuclein critical to the aggregation process. Through the use of structure based design, peptidomimetic and peptide compounds were designed that block alpha-synuclein aggregation and neurodegeneration in an in-vitro model system. The initial compounds or their derivatives may serve as lead compounds or core structures that mimic natural chaperones that inhibit aggregation. This approach represents a radical shift from current approaches where reactive dyes are used in conjunction with the aggregated proteins to screen large chemical libraries, which may contain reactive compounds but potentially lack the required high degree of specificity to be a viable therapeutic candidate.
8450481
Related Materials Additional Technologies by these Inventors Tech ID/UC Case 19415/2007-274-0 Related Cases 2007-274-0
美國
